VWA5A Antibody

What is VWA5A and why is it important in cancer research?

VWA5A is a tumor suppressor protein that plays a crucial role in breast cancer progression and metastasis. Research has shown that VWA5A is expressed at low levels in various tissues, with no expression found in approximately 80% of tumor cell lines . Its importance stems from its tumor suppressive properties, particularly in hormone receptor (HR)-positive breast cancers and triple-negative breast cancer cell lines. Low expression of VWA5A is associated with poor survival outcomes and increased metastatic potential, making it a valuable biomarker for cancer progression . For researchers, understanding VWA5A expression patterns can provide insights into the mechanisms of cancer metastasis and potential therapeutic targets.

What applications are VWA5A antibodies validated for in research settings?

VWA5A antibodies have been validated for multiple research applications:

When selecting antibodies for specific applications, researchers should verify the validation status for their particular experimental system . Most commercial antibodies provide application-specific validation data and recommended dilutions.

How should VWA5A antibodies be stored and handled to maintain optimal performance?

Proper storage and handling of VWA5A antibodies is critical for experimental success and reproducibility:

• Store primary antibodies at -20°C for long-term storage

• For frequent use, aliquot and store at 4°C for up to one month

• Avoid repeated freeze-thaw cycles as they can degrade antibody quality

• Most VWA5A antibodies are supplied in PBS with stabilizers (typically 0.05% sodium azide, 50% glycerol, pH 7.2-7.4)

• When diluting for use, prepare fresh working solutions in appropriate buffers

• Follow manufacturer's recommendations for specific formulations

For optimal experimental outcomes, always check the certificate of analysis for specific storage conditions, as they may vary slightly between suppliers .

What are the key considerations for validating VWA5A antibody specificity?

Validating antibody specificity is essential for reliable results. For VWA5A antibodies, consider these validation approaches:

• Positive and negative controls: Use cell lines with known VWA5A expression profiles. Research indicates reliable detection in cell lines such as Hela, NIH-3T3, and H9C2 .

• Knockdown/knockout verification: Perform siRNA knockdown of VWA5A (as demonstrated in T47D, BT20, and HCC70 cell lines) to confirm antibody specificity .

• Western blot analysis: Verify the detection of a single band at the expected molecular weight (~86 kDa).

• Cross-reactivity testing: Test across multiple species if conducting comparative studies. Many VWA5A antibodies react with human, mouse, and rat samples .

• Immunohistochemical patterns: Compare with established expression patterns - nuclear staining is particularly important as decreasing nuclear expression correlates with tumor progression .

Proper validation ensures experimental reliability and reproducibility, particularly when investigating VWA5A's role in cancer metastasis .

How can VWA5A expression be quantified in different breast cancer subtypes, and what are the known expression patterns?

Quantification of VWA5A expression across breast cancer subtypes requires specific methodological approaches:

Immunohistochemistry (IHC) Quantification:

• Use H-score method (0-300 scale) to evaluate nuclear VWA5A expression

• VWA5A-high groups typically comprise approximately 42.7% of breast cancer samples, while 57.3% show low expression

• Nuclear staining intensity correlates with prognosis and can be classified into high/low groups

Expression Patterns by Subtype:

For quantitative assessment, researchers should establish standardized scoring methods, preferably using digital image analysis to minimize inter-observer variation. Concordance index (c-index) values for VWA5A in predicting disease-free survival range from 0.518-0.545 depending on the breast cancer subtype .

What experimental approaches effectively demonstrate the functional role of VWA5A in cancer metastasis?

Several experimental approaches have proven effective for investigating VWA5A's functional role in cancer metastasis:

siRNA Knockdown Studies:

• Transfect breast cancer cell lines (e.g., T47D for HR+, BT20 and HCC70 for TNBC) with siVWA5A

• Confirm knockdown efficiency using RT-PCR

• Assess changes in cellular behavior through:

  • Invasion assays (e.g., Matrigel invasion chambers)

  • Migration assays (e.g., wound healing/scratch assays)

  • Cell proliferation assays (MTT or similar)

Cell Line Functional Analysis:

• Compare VWA5A expression levels across different breast cancer subtypes (luminal, HER2+, TNBC)

• Correlate expression with proliferation rates

• Research has shown that lower VWA5A expression leads to faster cell proliferation in luminal and TNBC cells, but interestingly, higher expression correlates with faster proliferation in HER2+ cells

In vitro Modeling of Metastatic Potential:

• Following VWA5A knockdown, HR+ cell lines (like T47D) show increased invasive and migratory behavior despite reduced proliferation capability

• This suggests VWA5A influences cell-intrinsic metastatic potential through mechanisms independent of proliferation

These methodological approaches provide comprehensive insights into VWA5A's role in regulating cancer cell metastasis.

What are the technical challenges in detecting VWA5A in clinical samples, and how can they be overcome?

Detecting VWA5A in clinical samples presents several technical challenges that researchers should address:

Fixation and Processing Effects:

• Formalin fixation can mask VWA5A epitopes, requiring optimization of antigen retrieval methods

• For FFPE tissue samples, citrate or EDTA-based antigen retrieval at pH 6.0 or 9.0 should be tested

• Optimal heat-induced epitope retrieval typically requires 15-20 minutes at 95-98°C

Expression Level Heterogeneity:

• VWA5A expression varies significantly between and within tumors

• Use tissue microarrays (TMAs) with multiple cores per sample to account for heterogeneity

• In a study of 1003 breast cancer patients, only 966 (96.3%) had adequate tumor cells for VWA5A IHC interpretation, highlighting sampling challenges

Nuclear vs. Cytoplasmic Staining:

• VWA5A shows predominantly nuclear staining pattern

• Clear guidelines for distinguishing and scoring nuclear vs. cytoplasmic staining are essential

• Nuclear staining has stronger prognostic significance and correlates with T stage and lymphatic invasion

Optimization Strategies:

• Test multiple antibody clones and dilutions (typically 1:100-1:500 for IHC)

• Include positive controls (normal breast tissue) and negative controls (omitting primary antibody)

• Consider multiplex IHC to correlate with other markers (e.g., hormone receptors)

• Standardize scoring methods, preferably using digital pathology platforms

By addressing these technical challenges, researchers can improve the reliability of VWA5A detection in clinical samples for both research and potential diagnostic applications.

How does VWA5A expression correlate with different stages of breast cancer metastasis, and what are the best experimental designs to study this relationship?

VWA5A expression shows distinct correlation patterns with breast cancer metastasis stages:

Expression-Metastasis Correlation:

• VWA5A expression decreases sequentially from non-metastatic (NM) to late metastasis (LM) to early metastasis (M) groups

• Quantitative measurements from proteomic studies show median LFQ intensities of 29.6 (NM), 29.2 (LM), and 28.2 (M)

• Lower VWA5A expression correlates significantly with advanced T stage (p = 0.014) and lymphatic invasion (p = 0.009)

Optimal Experimental Design for Studying This Relationship:

This comprehensive experimental approach allows researchers to establish both correlative and potentially causal relationships between VWA5A expression and metastatic progression in breast cancer.

What are the most effective protocols for optimizing VWA5A immunohistochemistry in different tissue types?

Optimizing VWA5A immunohistochemistry requires tissue-specific considerations:

General IHC Protocol Optimization:

• Fixation and Processing:

  • Optimal fixation: 10% neutral buffered formalin for 24-48 hours

  • Paraffin embedding following standard histological procedures

  • Section thickness: 4-5 μm for optimal staining

• Antigen Retrieval Methods:

  • Heat-induced epitope retrieval (HIER) is essential

  • Test both citrate buffer (pH 6.0) and EDTA buffer (pH 9.0)

  • Pressure cooker (15-20 min) or microwave methods (15-20 min at 95-98°C)

• Antibody Selection and Dilution:

  • Primary antibody dilutions typically range from 1:100-1:500

  • Incubation conditions: overnight at 4°C or 1-2 hours at room temperature

  • Secondary detection: polymer-based systems offer higher sensitivity than avidin-biotin methods

• Visualization Systems:

  • DAB (3,3'-diaminobenzidine) provides excellent contrast for nuclear staining

  • Counterstain with hematoxylin (light staining to avoid masking nuclear VWA5A signal)

Tissue-Specific Modifications:

Scoring and Interpretation:

• H-score system (intensity × percentage) for nuclear staining

• Digital image analysis for standardization

• Multiple TMA cores (minimum 3) for heterogeneity assessment

This optimized approach ensures reliable and reproducible VWA5A IHC staining across different tissue types.

How can researchers effectively integrate VWA5A protein expression data with other molecular markers in comprehensive breast cancer studies?

Integrating VWA5A expression data with other molecular markers requires a thoughtful multidimensional approach:

Multimodal Data Integration Strategies:

• Multiplex Immunohistochemistry/Immunofluorescence:

  • Co-stain for VWA5A with established markers:

    • Hormone receptors (ER, PR) - particularly relevant as VWA5A shows stronger prognostic value in HR+ tumors

    • HER2

    • Proliferation markers (Ki-67)

    • E-cadherin and α-catenin (shown to increase with abnormal VWA5A expression)

  • Use multispectral imaging systems for quantitative analysis

  • Apply tissue segmentation algorithms to analyze tumor and stromal compartments separately

• Proteogenomic Correlation Analysis:

  • Compare VWA5A protein expression (by IHC or mass spectrometry) with:

    • VWA5A gene expression (by RNA-seq or RT-PCR)

    • Copy number alterations (CNAs)

    • Mutation status

  • Analyze concordance/discordance patterns to identify post-transcriptional regulation

• Pathway Analysis and Network Integration:

  • Use network propagation (NP) and protein-protein interaction (PPI) analyses to identify functional relationships

  • Apply machine learning approaches like mutual information (MI) feature selection to identify correlated markers

  • Integrate with established breast cancer molecular subtypes (Luminal A/B, HER2+, Basal-like)

• Statistical Framework for Integration:

• Validation Strategy:

  • Use independent cohorts (e.g., METABRIC dataset was used to validate VWA5A findings)

  • Calculate concordance index (c-index) values to assess predictive performance

  • Apply cross-validation techniques to avoid overfitting

By implementing these integration strategies, researchers can position VWA5A within the broader molecular landscape of breast cancer, enhancing its clinical and biological relevance .

What are the critical experimental design considerations for studying VWA5A's role in tumor suppression across different cancer models?

When designing experiments to investigate VWA5A's tumor suppression role, researchers should consider:

Model Selection and Experimental Controls:

• Cell Line Selection:

  • Include multiple cell lines representing different cancer subtypes:

    • HR+ breast cancer (e.g., T47D, MCF7)

    • HER2+ breast cancer lines

    • Triple-negative breast cancer (e.g., BT20, HCC70, MDA-MB-231)

    • Non-breast cancer lines to assess tissue-specific effects

  • Match cell lines with baseline VWA5A expression levels (high, intermediate, low)

• Genetic Manipulation Approaches:

  • Loss-of-function studies:

    • siRNA knockdown (transient)

    • shRNA (stable knockdown)

    • CRISPR/Cas9 knockout

  • Gain-of-function studies:

    • Inducible expression systems

    • Stable transfection with different VWA5A expression constructs

  • Include appropriate vector controls for all manipulations

• Functional Assays and Endpoints:

• In Vivo Models:

  • Orthotopic implantation in immunocompromised mice

  • Patient-derived xenografts with varying VWA5A expression

  • Metastasis models to assess colonization efficiency

  • Consider timing of metastasis (early vs. late) in experimental design

• Statistical Power and Experimental Design:

  • Perform power calculations based on expected effect sizes

  • Use factorial designs when testing multiple conditions

  • Include time-course experiments to capture dynamic changes

  • Minimum n=3 biological replicates, with technical replicates for each assay

These comprehensive design considerations will enable robust assessment of VWA5A's tumor suppressor functions across different experimental contexts.

What approaches can researchers use to study the relationship between VWA5A expression and treatment response in breast cancer patients?

Investigating the relationship between VWA5A expression and treatment response requires systematic methodological approaches:

Clinical Cohort Study Design:

• Retrospective Analysis:

  • Select cohorts of patients with known treatment regimens:

    • Hormone therapy (for HR+ cancers)

    • Anti-HER2 therapies

    • Chemotherapy (various regimens)

  • Stratify by VWA5A expression (high vs. low) using standardized IHC scoring

  • Calculate treatment-specific hazard ratios and response rates

• Prospective Biomarker Studies:

  • Collect pre-treatment tissue samples

  • Measure baseline VWA5A expression by IHC

  • Track response metrics: RECIST criteria, pathological complete response (pCR), disease-free survival

  • Perform interim and final analyses with predetermined statistical plans

Translational Laboratory Approaches:

• Ex Vivo Drug Sensitivity Testing:

  • Isolate primary tumor cells from patient samples

  • Determine VWA5A expression levels

  • Perform drug sensitivity assays across treatment panels

  • Correlate response with VWA5A expression

• Cell Line Models with Variable VWA5A Expression:

  • Create isogenic cell lines with manipulated VWA5A levels

  • Test response to standard-of-care treatments

  • Measure endpoints including:

    • Apoptosis markers

    • Cell cycle arrest

    • DNA damage response

    • Treatment-induced senescence

Data Analysis Framework:

Validation Requirements:

• Independent validation cohorts to confirm findings

• Standardized IHC protocols with central pathology review

• Predefined cutoffs for VWA5A expression categorization

• Consideration of tumor heterogeneity through multiple sampling